CEO Watcher

Consider Alchemy Technology, where investment firm General Atlantic made a $29 million purchase, its first since 2022, with a track record of 40% average gains on its previous picks. The CEO of ICU Medical also signaled a potential rebound with a first-ever $2.5 million stock purchase after a recent 20% price decline. Conversely, two directors at Applevin sold a massive $240 million in stock following a 400% run-up, suggesting the shares may be overvalued. Finally, a record-sized insider sale at IMAX is a notable bearish signal, as this executive's past sales have historically preceded an average 9% stock decline in the following month.

A director at Bausch Health (BHC) made a $21 million purchase, and their past buys have historically averaged 34% returns within three months. Insiders at Xponential Fitness (XPOF) and Amplify Energy (AMPY) also made their largest-ever purchases after significant price drops, signaling strong conviction in a recovery. These bullish signals suggest insiders believe their stocks are currently undervalued. Conversely, executives at Carlyle Group (CG), Mirion Technologies (MIR), and Oshkosh (OSK) made their largest-ever sales after major stock run-ups. This pattern of insider selling indicates a belief that these stocks may be fully valued and could be due for a correction.

Multiple insiders are signaling strong confidence in Eli Lilly (LLY) by making their largest-ever stock purchases after a recent 20% price drop. Similarly, a director at Light & Wonder (LNW) made their largest-ever purchase, indicating bullish sentiment. Conversely, consider caution with Media Alpha (MAX), as a key executive with a highly accurate track record just made a significant sale. Historically, MAX stock has fallen an average of 42% within three months following this executive's sales. The CEO of Hims & Hers Health (HIMS) also showed a lack of confidence by selling over $30 million worth of stock.

The CEO of Hims & Hers Health (HIMS) made a record $5 million unscheduled sale after a 200% stock run-up, signaling a potential top for the shares. Similarly, top executives at Astera Labs (ALAB) sold over $50 million in stock after a 100% price surge, suggesting they are taking profits. On the buy side, the Executive Chairman of Shift4 Payments (FOUR) made his largest-ever purchase of $16.2 million following an 18% price drop, indicating strong belief in a recovery. A director at Becton Dickinson (BDX) also showed high conviction with a $1 million purchase; his past buys have preceded an average 23% gain within three months.